Our Versamune® platform trains the immune system to unleash a powerful targeted T-cell attack and could dramatically improve treatment and patient outcomes across the cancer spectrum.LEARN MORE
Our robust pipeline of promising cancer treatments is aimed at improving current cancer treatments by combining our products with FDA-approved standard of care and with other promising, clinical-stage immunotherapeutic agents.LEARN MORE
We have partnered with some of the world’s leading research institutions and pharmaceutical companies to develop more effective Versamune®-based cancer therapies and infectious disease vaccines to save lives.LEARN MORE
PDS Biotech is a clinical stage biopharmaceutical company with a growing pipeline of cancer immunotherapies and infectious disease vaccines. Our team is committed to developing first-in-class T-cell activating immunotherapies based on the Versamune® platform to fight against cancer. We are also developing novel preventive vaccines based on the Infectimune™ platform to provide more rapid and longer-lasting protection against infectious agents.